Ziprasidone
Geodon (ziprasidone) is a small molecule pharmaceutical. Ziprasidone was first approved as Geodon on 2001-02-05. It is used to treat schizophrenia, schizophrenia spectrum and other psychotic disorders, and tourette syndrome in the USA. The pharmaceutical is active against D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C. In addition, it is known to target 5-hydroxytryptamine receptor 1E, sodium-dependent serotonin transporter, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 7, histamine H1 receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1D, and sodium-dependent noradrenaline transporter.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Geodon (generic drugs available since 2012-03-02)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
geodon | New Drug Application | 2022-02-23 |
ziprasidone hydrochloride | ANDA | 2023-05-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
schizophrenia | EFO_0000692 | D012559 | F20 |
schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
tourette syndrome | EFO_0004895 | D005879 | F95.2 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
ZIPRASIDONE HYDROCHLORIDE, GEODON, VIATRIS | |||
2025-01-28 | M-232 |
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J3486 | Injection, ziprasidone mesylate, 10 mg |
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
Pulmonary heart disease | D011660 | I27.81 | — | — | — | — | 1 | 1 | |
Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | — | — | — | 1 | 1 |
Colorectal neoplasms | D015179 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ZIPRASIDONE |
INN | ziprasidone |
Description | Ziprasidone is a piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. It has a role as a psychotropic drug, a histamine antagonist, a muscarinic antagonist, a serotonergic antagonist, a dopaminergic antagonist and an antipsychotic agent. It is a member of piperazines, an organochlorine compound, a member of indolones and a 1,2-benzisothiazole. |
Classification | Small molecule |
Drug class | antipsychotic with binding activity on sertonin (5-HT2A) and dopamine (D2) receptors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1 |
Identifiers
PDB | — |
CAS-ID | 146939-27-7 |
RxCUI | 115698 |
ChEMBL ID | CHEMBL708 |
ChEBI ID | 10119 |
PubChem CID | 60854 |
DrugBank | DB00246 |
UNII ID | 6UKA5VEJ6X (ChemIDplus, GSRS) |
Target
Alternate
HTR1E
HTR1E
SLC6A4
SLC6A4
HTR1B
HTR1B
HTR7
HTR7
HRH1
HRH1
HTR1A
HTR1A
HTR1D
HTR1D
SLC6A2
SLC6A2
Variants
Clinical Variant
No data
Financial
Geodon - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,329 documents
View more details
Safety
Black-box Warning
Black-box warning for: Geodon, Ziprasidone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more